- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04479358
Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19 (COVIDOSE-2)
COVIDOSE-2: A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive Ventilation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
COVID-19's high mortality may be driven by hyperinflammation. Interleukin-6 (IL-6) axis therapies may reduce COVID-19 mortality. Retrospective analyses of tocilizumab in severe to critical COVID-19 patients have demonstrated survival advantage and lower likelihood of requiring invasive ventilation following tocilizumab administration. The majority of patients have rapid resolution (i.e., within 24-72 hours following administration) of both clinical and biochemical signs (fever and CRP, respectively) of hyperinflammation with only a single tocilizumab dose.
The investigators hypothesized that a dose of tocilizumab significantly lower than the EMA- and FDA-labeled dose (8mg/kg) as well as the emerging standard of care dose (400mg) may be effective in patients with COVID-19 pneumonitis and hyperinflammation. Advantages to the lower dose of tocilizumab may include lower likelihood of secondary bacterial infections as well as extension of this drug's limited supply. The investigators conducted an adaptive single-arm phase 2 trial (NCT04331795) evaluating clinical and biochemical response to low-dose tocilizumab in patients with COVID-19 pneumonitis and hyperinflammation.
This multi-center, prospective, randomized controlled phase 2 trial -- designed as two sub-studies to allow for the possible emergence of data demonstrating the clinical efficacy of tocilizumab 8mg/kg or 400mg -- formally tests the clinical efficacy of low-dose tocilizumab in COVID-19 pneumonia.
Sub-Study A Primary Objective A: To establish whether low-dose tocilizumab reduces the time to clinical recovery in patients with COVID-19 pneumonitis and hyperinflammation, when compared to a tocilizumab-free standard of care.
Hypothesis A: The investigators hypothesize that low-dose tocilizumab, when compared to a tocilizumab-free standard of care, decreases the time to recovery in hospitalized, non-invasively ventilated patients with COVID-19 pneumonitis and hyperinflammation by three days or more.
Sub-Study B Primary Objective B: To establish whether low-dose tocilizumab is near-equivalent to high-dose tocilizumab (400mg or 8 mg/kg) in reducing the time to clinical recovery in patients with COVID-19 pneumonitis and hyperinflammation.
Hypothesis B: The investigators hypothesize that low-dose tocilizumab is near-equivalent to high-dose tocilizumab in reducing the time to clinical recovery in hospitalized, non-invasively ventilated patients with COVID-19 pneumonitis and hyperinflammation.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Pankti D Reid, MD, MPH
- Phone Number: 7737021220
- Email: pankti.reid@uchospitals.edu
Study Contact Backup
- Name: Garth W Strohbehn, MD, MPhil
- Phone Number: 7737021220
- Email: gstrohbehn@uchicago.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults ≥ 18 years of age
- Approval from the patient's primary inpatient service
- Hospitalized
- Fever, documented in electronic medical record and defined as: T ≥ 38 degrees C by any conventional clinical method (forehead, tympanic, oral, axillary, rectal)
- Positive test for active SARS-CoV-2 infection
- Radiographic evidence of infiltrates on chest radiograph (CXR) or computed tomography (CT)
- Ability to provide written informed consent on the part of the subject or, in the absence of decisional capacity of the subject, an appropriate surrogate (e.g. a legally authorized representative).
Exclusion Criteria:
- Concurrent use of invasive mechanical ventilation
- Concurrent use of vasopressor or inotropic medications
- Previous receipt of tocilizumab or another anti-IL6R or IL-6 inhibitor in the year prior.
- Known history of hypersensitivity to tocilizumab.
- Diagnosis of end-stage liver disease or listed for liver transplant.
- Elevation of AST or ALT in excess of 10 times the upper limit of normal.
- Neutropenia (Absolute neutrophil count < 500/uL).
- Thrombocytopenia (Platelets < 50,000/uL).
- On active therapy with a Bruton's tyrosine kinase-targeted agent, which include the following:
- Acalabrutinib
- Ibrutinib
- Zanubrutinib
- On active therapy with a JAK2-targeted agent, which include the following:
- Tofacitinib
- Baricitinib
- Upadacitinib
- Ruxolitinib
- Any of the following biologic immunosuppressive agent (and any biosimilar versions thereof) administered in the past 6 months or less::
- Abatacept
- Adalimumab
- Alemtuzumab
- Atezolizumab
- Belimumab
- Blinatumomab
- Brentuximab
- Certolizumab
- Daratumumab
- Durvalumab
- Eculizumab
- Elotuzumab
- Etanercept
- Gemtuzumab
- Golimumab
- Ibritumomab
- Infliximab
- Inotuzumab
- Ipilimumab
- Ixekizumab
- Moxetumomab
- Nivolumab
- Obinutuzumab
- Ocrelizumab
- Ofatumumab
- Pembrolizumab
- Polatuzumab
- Rituximab
- Rituximab
- Sarilumab
- Secukinumab
- Tocilizumab
- Tositumumab
- Tremelimumab
- Urelumab
- Ustekinumab
- History of bone marrow transplantation (including chimeric antigen receptor T-cell) or solid organ transplant
- Known history of Hepatitis B or Hepatitis C (patients who have completed curative-intent anti-HCV treatments are not excluded from trial)
- Positive result on hepatitis B or C screening
- Known history of mycobacterium tuberculosis infection at risk for reactivation
- Known history of gastrointestinal perforation
- Active diverticulitis
- Multi-organ failure as determined by primary treating physicians
- Any other documented serious, active infection besides COVID-19 - including but not limited to: lobar pneumonia consistent with bacterial infection, bacteremia, culture-negative endocarditis, or current mycobacterial infection - at the discretion of primary treating physicians
- Pregnant patients or nursing mothers
- Patients who are unable to discontinue scheduled antipyretic medications, either as monotherapy (e.g., acetaminophen or ibuprofen [aspirin is acceptable]) or as part of combination therapy (e.g., hydrocodone/acetaminophen, aspirin/acetaminophen/caffeine [Excedrin®])
- CRP < 40 mg/L
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sub-study A, Tocilizumab-Free Standard of Care
Patient assigned to Sub-study A by primary treating physicians.
Patient enrolled on trial sub-study A and randomized to receive no tocilizumab.
|
Tocilizumab-Free Standard of Care
Tocilizumab 400mg or 8mg/kg
|
Experimental: Sub-study A, Tocilizumab 40mg
Patient assigned to Sub-study A by primary treating physicians.
Patient enrolled on trial sub-study A and randomized to receive tocilizumab 40mg.
|
Tocilizumab 40mg
Other Names:
Tocilizumab 120mg
Other Names:
|
Experimental: Sub-study A, Tocilizumab 120mg
Patient assigned to Sub-study A by primary treating physicians.
Patient enrolled on trial sub-study A and randomized to receive tocilizumab 120mg.
|
Tocilizumab 40mg
Other Names:
Tocilizumab 120mg
Other Names:
|
Active Comparator: Sub-study B, Tocilizumab 400mg or 8mg/kg Standard of Care
Patient assigned to Sub-study B by primary treating physicians.
Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab dose (400mg or 8mgkg).
|
Tocilizumab-Free Standard of Care
Tocilizumab 400mg or 8mg/kg
|
Experimental: Sub-study B, Tocilizumab 40mg
Patient assigned to Sub-study B by primary treating physicians.
Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 40mg.
|
Tocilizumab 40mg
Other Names:
Tocilizumab 120mg
Other Names:
|
Experimental: Sub-study B, Tocilizumab 120mg
Patient assigned to Sub-study B by primary treating physicians.
Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 120mg.
|
Tocilizumab 40mg
Other Names:
Tocilizumab 120mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Recovery
Time Frame: 28 days
|
Day of recovery is defined as the first day on which the patient achieves one of the following two categories from the seven-point ordinal scale: 6) Hospitalized, not requiring supplemental oxygen or ongoing medical care or 7) Not hospitalized.
Time to recovery is the number of days from randomization to achievement of this status.
Note that the ordinal scale is measured once daily, with the patient's worst clinical status during the 24-hour time period (0:00-23:59) being documented.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Achievement of Recovery
Time Frame: 7 days
|
This will be defined as the percentage of patients in a given arm of the study achieving one of the above two categories on the ordinal scale on day 7.
Note that the ordinal scale is measured once daily, with the patient's worst clinical status during the 24-hour time period (0:00-23:59) being documented.
|
7 days
|
Overall Survival
Time Frame: 28 days
|
This will be defined as the percentage of patients in a given arm of the study who are alive thirty days following randomization.
Patients who are discharged to hospice will be counted as deceased on the day of discharge.
Patients who are transitioned to inpatient hospice or inpatient comfort measures only will be counted as deceased on the day of transition.
|
28 days
|
Hospital Length of Stay
Time Frame: Up to 1 year
|
This will be defined as the number of days that pass between the day of a patient's randomization and his or her discharge from the hospital.
|
Up to 1 year
|
Clinical Response: Maximum Temperature (Tmax) Response
Time Frame: 24 hours
|
Maximum temperature within 24-hour periods of time immediately prior to, immediately following, and then every 24 hours thereafter randomization.
The primary endpoint is a measured Tmax in the 24-hour period immediately following randomization that is lower than the measured Tmax in the 24-hour period immediately preceding randomization.
|
24 hours
|
Clinical Response: Rate of Non-Elective Invasive Mechanical Ventilation
Time Frame: Up to 28 days
|
This will be a binary outcome defined as worsening COVID-19 disease resulting in the use of invasive mechanical ventilation during the course of the patient's COVID-19 infection.
|
Up to 28 days
|
Clinical Response: Duration of Non-Elective Invasive Mechanical Ventilation
Time Frame: Up to 28 days
|
This will be a continuous outcome defined by the amount of time between initiation and cessation of non-elective invasive mechanical ventilation.
|
Up to 28 days
|
Clinical Response: Time to Non-Elective Invasive Mechanical Ventilation
Time Frame: Up to 28 days
|
This will be a continuous outcome defined by the amount of time between randomization and the initiation of non-elective invasive mechanical ventilation.
This will be treated as a time-to-event with possible censoring.
|
Up to 28 days
|
Clinical Response: Rate of Vasopressor/Inotrope Utilization
Time Frame: Up to 28 days
|
This will be a binary outcome defined as utilization of any vasopressor or inotropic medication.
|
Up to 28 days
|
Clinical Response: Duration of Vasopressor/Inotrope Utilization
Time Frame: Up to 28 days
|
This will be a continuous outcome defined by the amount of time between initiation of first and cessation of last vasopressor medications.
|
Up to 28 days
|
Clinical Response: Time to Vasopressor/Inotrope Utilization
Time Frame: Up to 28 days
|
This will be a continuous outcome defined by the amount of time between randomization and the initiation of any vasopressor or inotropic medication.
This will be treated as a time-to-event with possible censoring.
|
Up to 28 days
|
Clinical Response: Duration of Increased Supplemental Oxygen from Baseline
Time Frame: 28 days
|
This will be an ordinal outcome defined by the number of days counted from randomization over which the participant requires supplemental oxygen in excess over his/her baseline supplemental oxygen requirement.
The supplemental oxygen requirement is defined as the highest liters-per-minute flow of supplemental oxygen required by the patient each day over the course of the hospitalization.
|
28 days
|
Biochemical Response: C-reactive Protein Response Rate
Time Frame: 24 hours
|
This will be a binary outcome defined as the presence or absence of a decline in CRP of ≥ 25% from baseline CRP in the 27 +/- 3 hours after tocilizumab administration, as compared to pre-treatment baseline.
|
24 hours
|
Safety: Rate of Secondary Infection
Time Frame: 28 days
|
This will be defined as the percentage of patients in a study arm who develop serious non-COVID-19 viral, bacterial, or fungal infections (e.g., bloodstream infection, hospital-acquired pneumonia, ventilator-associated pneumonia, opportunistic infection) following randomization and up to the 28-day assessment of overall survival.
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pankti D Reid, MD, MPH, University of Chicago
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB20-1179
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Standard of Care
-
brett rasmussenCompleted
-
Johns Hopkins UniversityRecruitingCompartment Syndrome of Leg | Extracorporeal Membrane Oxygenation Complication | Limb Ischemia, Critical | Limb IschemiaUnited States
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
Aventusoft, LLC.National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic FloridaRecruitingHeart Failure (HF)United States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedSevere COVID-19Israel
-
Ruijin HospitalRecruitingCOVID-19 PneumoniaChina
-
Institut Claudius RegaudCompletedMETASTATIC CANCERFrance
-
Ziv HospitalNot yet recruiting
-
Hofseth Biocare ASAKGK Science Inc.CompletedCovid-19 | COVIDCanada, Brazil, Hungary, Mexico, Serbia
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... and other collaboratorsCompleted